Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study
Abstract Background Multiparametric magnetic resonance imaging (MP-MRI) has high sensitivity for diagnosing breast cancers but cannot always be used as a routine diagnostic tool. The present study aimed to evaluate whether the diagnostic performance of perfluorobutane (PFB) contrast-enhanced ultraso...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-05-01
|
| Series: | Breast Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13058-023-01650-3 |
| _version_ | 1827933107542556672 |
|---|---|
| author | Manlin Lang Ping Liang Huiming Shen Hang Li Ning Yang Bo Chen Yixu Chen Hong Ding Weiping Yang Xiaohui Ji Ping Zhou ligang Cui Jiandong Wang Wentong Xu Xiuqin Ye Zhixing Liu Yu Yang Tianci Wei Hui Wang Yuanyuan Yan Changjun Wu Yiyun Wu Jingwen Shi Yaxi Wang Xiuxia Fang Ran li Jie Yu |
| author_facet | Manlin Lang Ping Liang Huiming Shen Hang Li Ning Yang Bo Chen Yixu Chen Hong Ding Weiping Yang Xiaohui Ji Ping Zhou ligang Cui Jiandong Wang Wentong Xu Xiuqin Ye Zhixing Liu Yu Yang Tianci Wei Hui Wang Yuanyuan Yan Changjun Wu Yiyun Wu Jingwen Shi Yaxi Wang Xiuxia Fang Ran li Jie Yu |
| author_sort | Manlin Lang |
| collection | DOAJ |
| description | Abstract Background Multiparametric magnetic resonance imaging (MP-MRI) has high sensitivity for diagnosing breast cancers but cannot always be used as a routine diagnostic tool. The present study aimed to evaluate whether the diagnostic performance of perfluorobutane (PFB) contrast-enhanced ultrasound (CEUS) is similar to that of MP-MRI in breast cancer and whether combining the two methods would enhance diagnostic efficiency. Patients and methods This was a head-to-head, prospective, multicenter study. Patients with breast lesions diagnosed by US as Breast Imaging Reporting and Data System (BI-RADS) categories 3, 4, and 5 underwent both PFB-CEUS and MP-MRI scans. On-site operators and three reviewers categorized the BI-RADS of all lesions on two images. Logistic-bootstrap 1000-sample analysis and cross-validation were used to construct PFB-CEUS, MP-MRI, and hybrid (PFB-CEUS + MP-MRI) models to distinguish breast lesions. Results In total, 179 women with 186 breast lesions were evaluated from 17 centers in China. The area under the receiver operating characteristic curve (AUC) for the PFB-CEUS model to diagnose breast cancer (0.89; 95% confidence interval [CI] 0.74, 0.97) was similar to that of the MP-MRI model (0.89; 95% CI 0.73, 0.97) (P = 0.85). The AUC of the hybrid model (0.92, 95% CI 0.77, 0.98) did not show a statistical advantage over the PFB-CEUS and MP-MRI models (P = 0.29 and 0.40, respectively). However, 90.3% false-positive and 66.7% false-negative results of PFB-CEUS radiologists and 90.5% false-positive and 42.8% false-negative results of MP-MRI radiologists could be corrected by the hybrid model. Three dynamic nomograms of PFB-CEUS, MP-MRI and hybrid models to diagnose breast cancer are freely available online. Conclusions PFB-CEUS can be used in the differential diagnosis of breast cancer with comparable performance to MP-MRI and with less time consumption. Using PFB-CEUS and MP-MRI as joint diagnostics could further strengthen the diagnostic ability. Trial registration Clinicaltrials.gov; NCT04657328. Registered 26 September 2020. IRB number 2020-300 was approved in Chinese PLA General Hospital. Every patient signed a written informed consent form in each center. |
| first_indexed | 2024-03-13T07:19:58Z |
| format | Article |
| id | doaj.art-480fa59ab9414dfc9aabd1ccc0762e1e |
| institution | Directory Open Access Journal |
| issn | 1465-542X |
| language | English |
| last_indexed | 2024-03-13T07:19:58Z |
| publishDate | 2023-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Breast Cancer Research |
| spelling | doaj.art-480fa59ab9414dfc9aabd1ccc0762e1e2023-06-04T11:42:24ZengBMCBreast Cancer Research1465-542X2023-05-0125111510.1186/s13058-023-01650-3Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter studyManlin Lang0Ping Liang1Huiming Shen2Hang Li3Ning Yang4Bo Chen5Yixu Chen6Hong Ding7Weiping Yang8Xiaohui Ji9Ping Zhou10ligang Cui11Jiandong Wang12Wentong Xu13Xiuqin Ye14Zhixing Liu15Yu Yang16Tianci Wei17Hui Wang18Yuanyuan Yan19Changjun Wu20Yiyun Wu21Jingwen Shi22Yaxi Wang23Xiuxia Fang24Ran li25Jie Yu26Department of Interventional Ultrasound, Fifth Medical Center of Chinese PLA General Hospital & Chinese PLA Medical SchoolDepartment of Interventional Ultrasound, Fifth Medical Center of Chinese PLA General HospitalDepartment of Ultrasound, Zhongda Hospital Southeast UniversityDepartment of Breast Surgery, Affiliated Hospital of Putian UniversityDepartment of Ultrasound, Xingcheng People’s HospitalDepartment of Ultrasound Medicine, Lu’an People’s Hospital of Anhui ProvinceDepartment of Ultrasound, The Fifth People’s Hospital of ChengduDepartment of Ultrasound, Huashan HospitalDepartment of Ultrasound, Guangxi Medical University Cancer HospitalDepartment of Ultrasound, The Fourth Hospital of Hebei Medical UniversityDepartment of Ultrasound, The Third Xiangya HospitalDepartment of Ultrasound, Peking University Third HospitalGeneral Surgery, Chinese PLA General HospitalGeneral Surgery, Chinese PLA General HospitalDepartment of Ultrasound, First Affiliated Hospital of Southern University of Science and Technology, Second Clinical College of Jinan University, Shenzhen Medical Ultrasound Engineering Center, Shenzhen People’s HospitalDepartment of Ultrasound Medicine, The First Affiliated Hospital of Nanchang UniversityDepartment of Ultrasound, Beijing Friendship HospitalDepartment of Ultrasound, The 2nd Affiliated Hospital of HarbinDepartment of Ultrasound, China-Japan Union Hospital of Jilin UniversityDepartment of Ultrasound, Zhengzhou Central HospitalDepartment of Ultrasonography, The First Affiliated Hospital of Harbin Medical UniversityDepartment of Ultrasound, Affiliated Hospital of Nanjing University of Chinese MedicineDepartment of Ultrasound, Shengjing Hospital of China Medical UniversityDepartment of Ultrasound, The Affiliated Hospital of Inner Mongolia Medical UniversityDepartment of Ultrasound, The Affiliated Hospital of Inner Mongolia Medical UniversityDepartment of Ultrasound, The First Affiliated Hospital of Xinxiang Medical UniversityDepartment of Interventional Ultrasound, Fifth Medical Center of Chinese PLA General HospitalAbstract Background Multiparametric magnetic resonance imaging (MP-MRI) has high sensitivity for diagnosing breast cancers but cannot always be used as a routine diagnostic tool. The present study aimed to evaluate whether the diagnostic performance of perfluorobutane (PFB) contrast-enhanced ultrasound (CEUS) is similar to that of MP-MRI in breast cancer and whether combining the two methods would enhance diagnostic efficiency. Patients and methods This was a head-to-head, prospective, multicenter study. Patients with breast lesions diagnosed by US as Breast Imaging Reporting and Data System (BI-RADS) categories 3, 4, and 5 underwent both PFB-CEUS and MP-MRI scans. On-site operators and three reviewers categorized the BI-RADS of all lesions on two images. Logistic-bootstrap 1000-sample analysis and cross-validation were used to construct PFB-CEUS, MP-MRI, and hybrid (PFB-CEUS + MP-MRI) models to distinguish breast lesions. Results In total, 179 women with 186 breast lesions were evaluated from 17 centers in China. The area under the receiver operating characteristic curve (AUC) for the PFB-CEUS model to diagnose breast cancer (0.89; 95% confidence interval [CI] 0.74, 0.97) was similar to that of the MP-MRI model (0.89; 95% CI 0.73, 0.97) (P = 0.85). The AUC of the hybrid model (0.92, 95% CI 0.77, 0.98) did not show a statistical advantage over the PFB-CEUS and MP-MRI models (P = 0.29 and 0.40, respectively). However, 90.3% false-positive and 66.7% false-negative results of PFB-CEUS radiologists and 90.5% false-positive and 42.8% false-negative results of MP-MRI radiologists could be corrected by the hybrid model. Three dynamic nomograms of PFB-CEUS, MP-MRI and hybrid models to diagnose breast cancer are freely available online. Conclusions PFB-CEUS can be used in the differential diagnosis of breast cancer with comparable performance to MP-MRI and with less time consumption. Using PFB-CEUS and MP-MRI as joint diagnostics could further strengthen the diagnostic ability. Trial registration Clinicaltrials.gov; NCT04657328. Registered 26 September 2020. IRB number 2020-300 was approved in Chinese PLA General Hospital. Every patient signed a written informed consent form in each center.https://doi.org/10.1186/s13058-023-01650-3PFB-CEUSMP-MRIHybridDiagnostic modelBreast lesionsDiagnostic performance |
| spellingShingle | Manlin Lang Ping Liang Huiming Shen Hang Li Ning Yang Bo Chen Yixu Chen Hong Ding Weiping Yang Xiaohui Ji Ping Zhou ligang Cui Jiandong Wang Wentong Xu Xiuqin Ye Zhixing Liu Yu Yang Tianci Wei Hui Wang Yuanyuan Yan Changjun Wu Yiyun Wu Jingwen Shi Yaxi Wang Xiuxia Fang Ran li Jie Yu Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study Breast Cancer Research PFB-CEUS MP-MRI Hybrid Diagnostic model Breast lesions Diagnostic performance |
| title | Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study |
| title_full | Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study |
| title_fullStr | Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study |
| title_full_unstemmed | Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study |
| title_short | Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study |
| title_sort | head to head comparison of perfluorobutane contrast enhanced us and multiparametric mri for breast cancer a prospective multicenter study |
| topic | PFB-CEUS MP-MRI Hybrid Diagnostic model Breast lesions Diagnostic performance |
| url | https://doi.org/10.1186/s13058-023-01650-3 |
| work_keys_str_mv | AT manlinlang headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT pingliang headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT huimingshen headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT hangli headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT ningyang headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT bochen headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT yixuchen headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT hongding headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT weipingyang headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT xiaohuiji headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT pingzhou headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT ligangcui headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT jiandongwang headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT wentongxu headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT xiuqinye headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT zhixingliu headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT yuyang headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT tianciwei headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT huiwang headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT yuanyuanyan headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT changjunwu headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT yiyunwu headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT jingwenshi headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT yaxiwang headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT xiuxiafang headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT ranli headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy AT jieyu headtoheadcomparisonofperfluorobutanecontrastenhancedusandmultiparametricmriforbreastcanceraprospectivemulticenterstudy |